RECURRENT GENE FUSIONS IN PROSTATE CANCER
First Claim
Patent Images
1. A composition comprising an oligonucleotide probe comprising a sequence that hybridizes to a junction of a chimeric nucleic acid molecule in which a 5′
- portion of the chimeric nucleic acid molecule is from a TMPRSS2 gene and a 3′
portion of the chimeric nucleic acid molecule is from an ETS family member gene, wherein the ETS family member gene is selected from the group consisting of ERG, ETV1 (ER81), FLI1, ETS1, ETS2, ELK1, ETV6 (TEL1), ETV7 (TEL2), GABPα
, ELF1, ETV4 (E1AF;
PEA3), ETV5 (ERM), ERF, PEA3/E1AF, PU.1, ESE1/ESX, SAP1 (ELK4), ETV3 (METS), EWS/FLI1, ESE1, ESE2 (ELF5), ESE3, PDEF, NET (ELK3;
SAP2), NERF (ELF2), and FEV.
4 Assignments
0 Petitions
Accused Products
Abstract
Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.
13 Citations
26 Claims
-
1. A composition comprising an oligonucleotide probe comprising a sequence that hybridizes to a junction of a chimeric nucleic acid molecule in which a 5′
- portion of the chimeric nucleic acid molecule is from a TMPRSS2 gene and a 3′
portion of the chimeric nucleic acid molecule is from an ETS family member gene, wherein the ETS family member gene is selected from the group consisting of ERG, ETV1 (ER81), FLI1, ETS1, ETS2, ELK1, ETV6 (TEL1), ETV7 (TEL2), GABPα
, ELF1, ETV4 (E1AF;
PEA3), ETV5 (ERM), ERF, PEA3/E1AF, PU.1, ESE1/ESX, SAP1 (ELK4), ETV3 (METS), EWS/FLI1, ESE1, ESE2 (ELF5), ESE3, PDEF, NET (ELK3;
SAP2), NERF (ELF2), and FEV. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- portion of the chimeric nucleic acid molecule is from a TMPRSS2 gene and a 3′
-
16. A composition comprising an oligonucleotide probe comprising a sequence that hybridizes to a junction of a chimeric nucleic acid molecule in which a 5′
- portion of the chimeric nucleic acid molecule is from a TMPRSS2 gene and a 3′
portion of the chimeric nucleic acid molecule is from an ERG gene. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23)
- portion of the chimeric nucleic acid molecule is from a TMPRSS2 gene and a 3′
-
24. A composition comprising a hybridized oligonucleotide:
- target gene fusion duplex, wherein the target gene fusion comprises a fusion of a TMPRSS2 gene with an ERG, an ETV1, or an ETV4 gene, wherein the oligonucleotide is hybridized to a junction of a chimeric nucleic acid molecule in which a 5′
portion of the nucleic acid molecule is from a TMPRSS2 gene and a 3′
portion of the nucleic acid molecule is from the ERG, the ETV1, or the ETV4 gene, and wherein the target gene fusion is obtained from a tissue, blood, urine, semen, prostatic secretion, plasma, serum, urine supernatant, urine cell pellet, or prostate cell sample. - View Dependent Claims (25, 26)
- target gene fusion duplex, wherein the target gene fusion comprises a fusion of a TMPRSS2 gene with an ERG, an ETV1, or an ETV4 gene, wherein the oligonucleotide is hybridized to a junction of a chimeric nucleic acid molecule in which a 5′
Specification